Galmed Pharmaceuticals has recently received a letter from the Nasdaq Listing Qualifications, informing them that they are currently not meeting the minimum bid price requirement for continued listing, as stated in Listing Rule 5550(a)(2). This rule mandates that listed securities must maintain a minimum bid price of $1.00 per share.
According to the letter, Galmed Pharmaceuticals has been granted a compliance period of 180 calendar days, starting from September 18, 2023, until March 18, 2024, to regain compliance. During this timeframe, the company can regain compliance if the closing bid price of its ordinary shares reaches or exceeds $1 for a minimum of ten consecutive business days.
However, if Galmed Pharmaceuticals fails to demonstrate compliance by the end of the 180-day period, they will receive notification from the Nasdaq’s staff regarding the potential delisting of their ordinary shares.
Nevertheless, there is a possibility for Galmed Pharmaceuticals to be eligible for an additional extension if they meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. In this case, the company will need to provide written notice of its intention to cure the deficiency during the second compliance period.
Galmed Pharmaceuticals Ltd.
Updated on: 01/03/2024
Debt to equity ratio: Sell
Price to earnings ratio: Sell
Price to book ratio: Neutral
DCF: Strong Buy
We did not find social sentiment data for this stock
There are no analysts data to display
Stock Performances on September 22, 2023: ENDPQ, NBSE, and HSTO Analysis and Insights
Stock Performances on September 22, 2023: A Closer Look at ENDPQ, NBSE, and HSTO
On September 22, 2023, several stocks experienced notable performances. Let’s dive into the stock performances of ENDPQ, NBSE, and HSTO on this particular day.
ENDPQ began the day with a previous close of $0.60 and opened at $0.62. Throughout the day, its price fluctuated within a range of $0.62 to $0.63. The stock had a volume of 295. With a market cap of $2.8 million, ENDPQ had displayed impressive earnings growth of +46.16% in the previous year. However, no data was available for earnings growth this year or revenue growth last year. The Price/Book was reported as 0.09.
NBSE faced a decline on September 22, 2023, as its stock price dropped by $0.12 or 12.00%. This negative change resulted in a new price of $0.88.
In contrast to NBSE, HSTO showed positive growth, with its stock price increasing by $0.06 or 11.75%. This upward movement brought the stock’s price to $0.57. HSTO is expected to report its next earnings on November 6, 2023, with an EPS forecast of -$1.50. The company reported no annual revenue last year, and its annual profit was -$17.9 million.
In terms of the sector and industry, ENDPQ operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The corporate headquarters of ENDPQ are located in Tel Aviv, Tel Aviv.
Overall, ENDPQ, NBSE, and HSTO experienced different performances on September 22, 2023. While ENDPQ showed stability with a minor price increase, NBSE faced a decline. On the other hand, HSTO demonstrated positive growth. Investors and market analysts will continue to monitor these stocks to assess their future performances and potential opportunities.
GLMD Stock Soars on September 22, 2023: Galmed Pharmaceuticals Sees Impressive Increase in Price
GLMD stock had an impressive performance on September 22, 2023, as it saw a significant increase in its price. According to the data provided by CNN Money, Galmed Pharmaceuticals Ltd had a median target price of $4.00, with a high estimate and low estimate also at $4.00. This median estimate represents a substantial 545.27% increase from the last recorded price of $0.62.
The consensus among one polled investment analyst is to buy stock in Galmed Pharmaceuticals Ltd. This rating has remained steady since July, when it was upgraded from a hold rating. This suggests that the analyst believes in the company’s potential for growth and sees it as a favorable investment opportunity.
It is important to note that Galmed Pharmaceuticals Ltd is a pharmaceutical company, and its stock performance is influenced by various factors such as clinical trial results, regulatory approvals, and market demand for its products. Investors should consider these factors before making any investment decisions.
Looking at the current financials of Galmed Pharmaceuticals Ltd, the company reported earnings per share of -$1.50 for the current quarter. This indicates that the company incurred a loss during this period. However, it is essential to consider the context and the company’s long-term prospects rather than focusing solely on short-term financial results.
The sales for the current quarter were reported as $0.00, which suggests that the company did not generate any revenue during this period. It is worth noting that pharmaceutical companies often have uneven revenue streams due to the nature of their business, which heavily relies on research and development and regulatory processes.
Investors should keep an eye on Galmed Pharmaceuticals Ltd’s upcoming reporting date, which is scheduled for November 6. This will provide further insights into the company’s financial performance and any updates on its pipeline of drugs or potential partnerships.
In conclusion, GLMD stock had a positive performance on September 22, 2023, with a significant increase in its price. The consensus among analysts is to buy stock in Galmed Pharmaceuticals Ltd, indicating confidence in its growth potential. However, investors should carefully consider the company’s financials, upcoming reporting date, and other relevant factors before making any investment decisions.